These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35887766)

  • 1. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
    Sun Y; Li Z; Jian H; Xia L; Lu S
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
    Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
    Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of
    Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 7. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
    Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
    Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immunotherapy in
    Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
    Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis.
    Gu X; Si J; Guan Y; Xu Y; Shao L; Zhang Y; Xu C; Pan W; Lu Y; Song Z; Wang W
    Open Med (Wars); 2023; 18(1):20230653. PubMed ID: 36915627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
    Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
    Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
    JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare
    Jiang H; Li Y; Wang Y; Zou B; Chen Y; Zhang Y; Husain H; Forest F; Qian F; Zhang L; Zhou C; Liu H; Wang D; Zhang W; Lu J; Han B
    Transl Lung Cancer Res; 2024 Jul; 13(7):1672-1684. PubMed ID: 39118889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
    Pavan A; Bragadin AB; Calvetti L; Ferro A; Zulato E; Attili I; Nardo G; Dal Maso A; Frega S; Menin AG; Fassan M; Calabrese F; Pasello G; Guarneri V; Aprile G; Conte P; Rosell R; Indraccolo S; Bonanno L
    Transl Lung Cancer Res; 2021 Jan; 10(1):202-220. PubMed ID: 33569305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and immune phenotypes associated with
    Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
    J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.
    Ghimessy AK; Gellert A; Schlegl E; Hegedus B; Raso E; Barbai T; Timar J; Ostoros G; Megyesfalvi Z; Gieszer B; Moldvay J; Renyi-Vamos F; Lohinai Z; Hoda MA; Klikovits T; Klepetko W; Laszlo V; Dome B
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31600989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.